RxDoctor Payments Data

Jonathan Overdevest, MD

Otolaryngology · New York, NYNPI 1881945657

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,020 of the $12,700 with a category attached, or 78.9%. Sanofi accounts for 88.9% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $9,076, more than ten times the $478 reported in 2019. Among otolaryngology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,700in general payments, 2019–2025

Across 30 payments — averaging $423.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$11K
  • Intersect ENT, Inc.$702
  • Stryker$336
  • Medtronic$298
  • Optinose US, Inc.$69

What the payments were for

  • Consulting fees$10,02079%
  • Travel & lodging$7746%
  • Food & beverage$1,90615%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi15$11,295
Intersect ENT, Inc.5$702
Stryker6$336
Medtronic(2 entities)3$298
Optinose US, Inc.1$69

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,700 in reported general payments places this provider in the 90th percentile of 701 otolaryngology providers in New York.

See all otolaryngology providers in New York

Medicare billing

Part B allowed, 2024
$115,388
Medicare patients
214
Services billed
569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate15$21,958
Ipratropium Bromide330$6,980
LumiganBimatoprost11$5,430
Azelastine Hcl203$3,199
Fluticasone Propionate245$2,168
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav45$502
Omeprazole38$433
Mupirocin35$216
Methylprednisolone18$142
Doxycycline Hyclate13$98
Prednisone17$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$69$21,95815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 701 otolaryngology providers in New York.

Other otolaryngology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →